Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-World 30-Day Mortality After the Last Dose of Immune Checkpoint Inhibitors: A Multicenter Retrospective Cohort Study in Turkey.

Current oncology (Toronto, Ont.)·2026

Same author

Limb Compression Therapy and Chemotherapy-Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self-Controlled Study(NEURO-GLOVE Trial).

International journal of cancer·2026

Same author

Expanding perspectives on informed decision-making in pancreatic cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Same author

Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study.

Medicina (Kaunas, Lithuania)·2026

Same author

Ovarian Metastasis from EBV-Associated Undifferentiated Nasopharyngeal Carcinoma: An Exceptionally Rare Occurrence.

Anticancer research·2026

Same author

Key Methodological Considerations in the Interpretation of the CONKO-007 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

The relationship between clinical and pathological findings and FDG - PET uptake in metastatic colorectal cancers.

Bediz Kurt İnci¹, Fatih Gürler, Osman Sütcüoğlu

¹Department of Medical Oncology, Gazi University Faculty of Medicine Hospital, Ankara, Turkey.

Indian Journal of Cancer

|March 7, 2024

Summary

This summary is machine-generated.

This study found no significant link between KRAS mutations and 18F-FDG PET/CT scan uptake in metastatic colorectal cancer (mCRC). However, BRAF mutations and certain tumor markers correlated with higher PET scan values in specific metastatic sites.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Related Experiment Videos

Last Updated: Jun 15, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Area of Science:

Oncology
Nuclear Medicine
Molecular Imaging

Background:

Metastatic colorectal cancer (mCRC) exhibits potential differences in genetic makeup and metabolism between primary and metastatic lesions.
Cellular glucose metabolism may vary in RAS wild-type versus mutant mCRC, impacting patient prognosis.

Purpose of the Study:

To compare 2-deoxy-2-[18F]-fluoro-D-glucose Positron Emission Tomography (18F-FDG PET/CT) uptake levels in relation to KRAS mutation status and primary-metastatic tumor localization in mCRC.
To investigate the association between tumor markers and metabolic activity in mCRC.

Main Methods:

Retrospective cohort analysis of mCRC patients.
Evaluation of RAS mutation status.
Staging-oriented 18F-FDG PET/CT scans were analyzed.

Main Results:

No significant relationship was found between KRAS mutational status and maximum Standardized Uptake Value (SUVmax) in primary or metastatic tumors.
Patients with liver metastasis and mutant BRAF status showed significantly higher SUVmax (P = 0.04).
Elevated carcinoembryonic antigen (CEA) and CA19-9 levels correlated with higher SUVmax in lung, liver, peritoneal, and bone metastases, respectively. Right-sided mCRC liver metastases had higher SUVmax (P = 0.03).

Conclusions:

A significant association between KRAS mutation and SUVmax values on PET scans in primary or metastatic sites of advanced CRC could not be established.
Tumor markers and BRAF mutation status may influence metabolic activity in specific metastatic sites of mCRC.